Monitoring brain tumor progression is a complex balancing act between objective imaging and subjective clinical changes. In a ...
FDA expanded zongertinib’s accelerated approval to treatment-naïve HER2-mutant advanced NSCLC, contingent on mutation ...
The FDA has liberated the second of two Intellia Therapeutics clinical trials that were put on hold last October following a report of serious liver toxicity that later led to death.
Shares of uniQure plummeted more than 40% in premarket trading Monday after the company confirmed the FDA has rejected its current data package for AMT-130, a highly anticipated gene therapy for ...
Qure stock plunged 45% after FDA rejected AMT-130 approval pathway, requiring new randomized trial for Huntington's disease gene therapy program.
Research Capital analyst Andre Uddin maintained his “Speculative Buy” rating and C$3.50 price target on Spectral Medical.
Enrollment for liMeliGhT, the first and largest gene therapy registrational trial for broad retinitis pigmentosa (RP) patients, was completed, ...
Moby 2025 Performance and Strategic Execution. Achieved a defining milestone of financial self-sustainability, effec ...
WHEN Frankie struggled to sit upright like other toddlers, mum Amy Sheridan-Hill initially thought there was “nothing to ...
13h
Zymeworks Provides Corporate Update and Reports Fourth Quarter and Full Year 2025 Financial Results
Supplemental Biologics License Application for Ziihera® (zanidatamab-hrii) to be completed by our partner Jazz in first-line HER2-positive ...
This article explores current OSD development and manufacturing trends from a CDMO perspective, including the evolution of outsourcing, emerging technologies, manufacturing advancements and industry ...
Q4 revenue -- $67.3 million reported for the quarter ended Dec. 31, 2025, compared to $1.5 million in Q4 2024; increase driven primarily by AstraZeneca and Gilead (NASDAQ:GILD) payments. Full-year ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results